Atezolizumab is a monoclonal antibody that functions as an immune checkpoint inhibitor, specifically targeting the programmed death-ligand 1 (PD-L1). It is mainly used to treat various cancers, including non-small cell lung cancer and urothelial carcinoma. It is grouped under the following drug class(es): Antineoplastic agents, Checkpoint inhibitors and Monoclonal antibodies. Its therapeutic use is listed as anti-cancer agents. The directory classifies it as a commercial API with a biotechnology source/manufacturing origin. Other names for this substance include Tecentriq, anti-PDL1 and atezolizumabum. Its PubChem SID is 481101521.
Atezolizumab
| CAS No | 1380723-44-3 |
|---|---|
| Molecular Formula | C₆₄₄₆H₉₉₀₂N₁₇₀₆O₁₉₉₈S₄₂ |
| Molecular Weight | ~144,610 Da |
| Synonyms | N/A |
Zoho Contact Form
"*" indicates required fields
Frequently Asked Questions
Atezolizumab is a monoclonal antibody that functions as an immune checkpoint inhibitor, specifically targeting the programmed death-ligand 1 (PD-L1). It is mainly used to treat various cancers, including non-small cell lung cancer and urothelial carcinoma.
The listed CAS number is 1380723-44-3.
The listed molecular formula is C₆₄₄₆H₉₉₀₂N₁₇₀₆O₁₉₉₈S₄₂.
The listed molecular weight is ~144,610 Da.
N/A.
The source lists Tecentriq, anti-PDL1 and atezolizumabum.